Reemergence of intravenous drug use as risk factor for Candidemia, Massachusetts, USA

Emerging Infectious Diseases

Volumn 24, Issue 4, 2018, Pages 631-637

  Poowanawittayakom, Nongnooch ^a   Dutta, Anamika ^b   Stock, Shannon ^b   Touray, Sunkaru ^a   Ellison, Richard T ^a   Levitz, Stuart M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b College of the Holy Cross   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANDIDA ALBICANS; CANDIDEMIA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE RE-EMERGENCE; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG USE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PREVALENCE; RISK FACTOR; COMMUNICABLE DISEASE; COMORBIDITY; COMPLICATION; MASSACHUSETTS; OUTCOME ASSESSMENT; RISK ASSESSMENT; SUBSTANCE ABUSE; YOUNG ADULT;

ADULT; CANDIDEMIA; COMMUNICABLE DISEASES, EMERGING; COMORBIDITY; DRUG USERS; FEMALE; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 85044216945     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2404.171807     Document Type: Article

References (20)

1. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the Prospective Antifungal Therapy Alliance registry. Clin Infect Dis. 2009; 48: 1695-703. http://dx.doi.org/10.1086/599039
2. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg DA, et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med. 2008; 36: 1993-8. http://dx.doi.org/10.1097/CCM.0b013e31816fc4cd
3. Playford EG, Marriott D, Nguyen Q, Chen S, Ellis D, Slavin M, et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med. 2008; 36: 2034-9. http://dx.doi.org/10.1097/CCM.0b013e3181760f42
4. Playford EG, Nimmo GR, Tilse M, Sorrell TC. Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999-2008. J Hosp Infect. 2010; 76: 46-51. http://dx.doi.org/10.1016/j.jhin.2010.01.022
5. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015; 373: 1445-56. http://dx.doi.org/10.1056/NEJMra1315399
6. Katz J. You draw it: just how bad is the drug overdose epidemic? 2017 [cited 2017 Sept 5]. https://www.nytimes.com/interactive/2017/04/14/upshot/drug-overdose-epidemic-you-draw-it.html?_r=0
7. Commonwealth of Massachusetts. Current opioid statistics. 2017 [cited 2018 Jan 9]. https://www.mass.gov/lists/current-opioid-statistics
8. Bisbe J, Miro JM, Latorre X, Moreno A, Mallolas J, Gatell JM, et al. Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. Clin Infect Dis. 1992; 15: 910-23. http://dx.doi.org/10.1093/clind/15.6.910
9. Dupont B, Drouhet E. Cutaneous, ocular, and osteoarticular candidiasis in heroin addicts: new clinical and therapeutic aspects in 38 patients. J Infect Dis. 1985; 152: 577-91. http://dx.doi.org/10.1093/infdis/152.3.577
10. Miró JM, De La Bellacasa J, Odds FC, Gill BK, Bisbe J, Gatell JM, et al. Systemic candidiasis in Spanish heroin addicts: a possible source of infection. J Infect Dis. 1987; 156: 857-8. http://dx.doi.org/10.1093/infdis/156.5.857
11. Podzamczer D, Fernández-Viladrich P, Ribera M, Arruga J, de Celis G, Gudiol F. Systemic candidiasis in drug addicts. Eur J Clin Microbiol. 1985; 4: 509-12. http://dx.doi.org/10.1007/BF02014437
12. Shankland GS, Richardson MD, Dutton GN. Source of infection in candida endophthalmitis in drug addicts. Br Med J (Clin Res Ed). 1986; 292: 1106-7. http://dx.doi.org/10.1136/bmj.292.6528.1106-a
13. Cassoux N, Bodaghi B, Lehoang P, Edel Y. Presumed ocular candidiasis in drug misusers after intravenous use of oral high dose buprenorphine (Subutex). Br J Ophthalmol. 2002; 86: 940-1. http://dx.doi.org/10.1136/bjo.86.8.940
14. Aboltins CA, Allen P, Daffy JR. Fungal endophthalmitis in intravenous drug users injecting buprenorphine contaminated with oral Candida species. Med J Aust. 2005; 182: 427.
15. Rodrigues CF, Silva S, Henriques M. Candida glabrata: a review of its features and resistance. Eur J Clin Microbiol Infect Dis. 2014; 33: 673-88. http://dx.doi.org/10.1007/s10096-013-2009-3
16. Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev. 2008; 21: 606-25. http://dx.doi.org/10.1128/CMR.00013-08
17. Centers for Disease Control and Prevention. Viral hepatitis. Statistics and surveillance. 2017 [cited 2017 Sept 5]. https://www.cdc.gov/hepatitis/statistics/index.htm
18. Commonwealth of Massachusetts. Shifting epidemics. HIV and hepatitis C infection among injection drug users in Massachusetts. 2012 [cited 2017 Sept 5]. http://www.mass.gov/eohhs/docs/dph/aids/shifting-epidemics-report.doc
19. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 62: 409-17. http://dx.doi.org/10.1093/cid/civ1194
20. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al.; Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007; 356: 2472-82. http://dx.doi.org/10.1056/NEJMoa066906